GlassScriptPhysician profile
Paul C Sedgwick
NPI 1366559460
$4,269.55
in general payments reported to CMS, 2019-2025
26 companies · $744 in 2025
The $744 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $214 · 2021: $501 · 2022: $858 · 2023: $597 · 2024: $546 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,886.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $514.74 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $412.73 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $382.41 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $345.98 | 2019-2022 | |
| Lilly USA, LLC | $341.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $299.33 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.40 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.74 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $245.30 | 2022-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $200.86 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $154.51 | 2023-2025 | Sunosi |
| Allergan, INC. | $126.44 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $85.76 | 2022 | |
| Mylan Specialty L.P. | $81.80 | 2023-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $75.12 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $68.88 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $60.74 | 2021 | |
| Abbott Laboratories | $59.47 | 2022-2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $53.51 | 2025 | Zoryve |
| Ardelyx, INC. | $53.35 | 2024-2025 | Ibsrela |
| Idorsia Pharmaceuticals US INC | $44.60 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $42.89 | 2019 | |
| Viatris Specialty LLC | $23.38 | 2025 | Yupelri |
| Intercept Pharmaceuticals, INC. | $17.85 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2019 | |
| Dexcom, INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sedgwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.